This HTML5 document contains 47 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n13http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n14http://linked.opendata.cz/resource/domain/vavai/subjekt/
n10http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00064165%3A_____%2F13%3A10173697%21RIV14-MZ0-00064165/
n9http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n18http://bibframe.org/vocab/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n4http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n12http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n15http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n8http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n19http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n16http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n11http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00064165%3A_____%2F13%3A10173697%21RIV14-MZ0-00064165
rdf:type
n9:Vysledek skos:Concept
rdfs:seeAlso
http://dx.doi.org/10.1159/000348634
dcterms:description
ANCA-associated vasculitis (AAV) is a potentially life-threatening disease with frequent and often severe kidney involvement which may result in end-stage renal disease. Anti-PR3 and anti-MPO disease are genetically distinct diseases and may have a different pathogenesis. Recent discovery of new autoantibodies (anti-LAMP-2) and the role of complement activation in the pathogenesis of AAV could result in better monitoring of the activity of the disease and identification of new treatment targets. The outcome of patients with AAV has dramatically improved, but long-term mortality still remains relatively high partly due to effective but relatively toxic immunosuppressive treatment. Recent studies demonstrated that B-cell depletion with rituximab is comparable to cyclophosphamide as induction treatment in newly diagnosed AAV patients and better than cyclophosphamide in relapsing patients. Rituximab-based maintenance treatment is superior to standard treatment with azathioprine. The use of more targeted treatment will hopefully be translated into a better long-term outcome of AAV patients. ANCA-associated vasculitis (AAV) is a potentially life-threatening disease with frequent and often severe kidney involvement which may result in end-stage renal disease. Anti-PR3 and anti-MPO disease are genetically distinct diseases and may have a different pathogenesis. Recent discovery of new autoantibodies (anti-LAMP-2) and the role of complement activation in the pathogenesis of AAV could result in better monitoring of the activity of the disease and identification of new treatment targets. The outcome of patients with AAV has dramatically improved, but long-term mortality still remains relatively high partly due to effective but relatively toxic immunosuppressive treatment. Recent studies demonstrated that B-cell depletion with rituximab is comparable to cyclophosphamide as induction treatment in newly diagnosed AAV patients and better than cyclophosphamide in relapsing patients. Rituximab-based maintenance treatment is superior to standard treatment with azathioprine. The use of more targeted treatment will hopefully be translated into a better long-term outcome of AAV patients.
dcterms:title
ANCA-Associated Renal Vasculitis - An Update ANCA-Associated Renal Vasculitis - An Update
skos:prefLabel
ANCA-Associated Renal Vasculitis - An Update ANCA-Associated Renal Vasculitis - An Update
skos:notation
RIV/00064165:_____/13:10173697!RIV14-MZ0-00064165
n9:predkladatel
n14:ico%3A00064165
n3:aktivita
n8:I n8:V
n3:aktivity
I, V
n3:cisloPeriodika
2013
n3:dodaniDat
n11:2014
n3:domaciTvurceVysledku
n13:1980505 n13:5909627
n3:druhVysledku
n19:J
n3:duvernostUdaju
n12:S
n3:entitaPredkladatele
n10:predkladatel
n3:idSjednocenehoVysledku
61222
n3:idVysledku
RIV/00064165:_____/13:10173697
n3:jazykVysledku
n15:eng
n3:klicovaSlova
randomized-trial; wegeners-granulomatosis; term-follow-up; daily oral cyclophosphamide; refractory granulomatous manifestations; small-vessel vasculitis; antineutrophil cytoplasmic autoantibodies; antibody-associated vasculitis
n3:klicoveSlovo
n4:term-follow-up n4:daily%20oral%20cyclophosphamide n4:randomized-trial n4:wegeners-granulomatosis n4:small-vessel%20vasculitis n4:antibody-associated%20vasculitis n4:antineutrophil%20cytoplasmic%20autoantibodies n4:refractory%20granulomatous%20manifestations
n3:kodStatuVydavatele
CH - Švýcarská konfederace
n3:kontrolniKodProRIV
[F7A071486C93]
n3:nazevZdroje
Contributions to Nephrology
n3:obor
n16:FE
n3:pocetDomacichTvurcuVysledku
2
n3:pocetTvurcuVysledku
2
n3:rokUplatneniVysledku
n11:2013
n3:svazekPeriodika
181
n3:tvurceVysledku
Hrušková, Zdenka Tesař, Vladimír
n3:wos
000322846600023
s:issn
0302-5144
s:numberOfPages
13
n18:doi
10.1159/000348634